Scarica l'app Stockscreener
11.74
3.62%
0.41
Dopo l'orario di chiusura:
11.75
0.010
+0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$11.33
Aprire:
$11.24
Volume 24 ore:
1.96M
Relative Volume:
0.81
Capitalizzazione di mercato:
$3.48B
Reddito:
$423.49M
Utile/perdita netta:
$-147.07M
Rapporto P/E:
-18.34
EPS:
-0.64
Flusso di cassa netto:
$-88.03M
1 W Prestazione:
+2.18%
1M Prestazione:
+10.75%
6M Prestazione:
+12.88%
1 anno Prestazione:
+1.38%
Intervallo 1D:
$11.21
$11.75
Intervallo di 1 settimana:
$11.21
$11.75
Portata 52W:
$9.02
$14.57
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(215) 921-7600
Indirizzo
3675 MARKET STREET, PHILADELPHIA, NJ
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Amicus Therapeutics Q3 2024 Earnings Preview - MSN
Creative Planning Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Bradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock - MarketBeat
Amicus Therapeutics CEO Bradley Campbell sells $85,959 in stock By Investing.com - Investing.com Canada
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know - Yahoo Finance
Allspring Global Investments Holdings LLC Has $172,000 Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - Defense World
Blue Trust Inc. Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 - GlobeNewswire
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - MarketBeat
abrdn plc Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by StockNews.com - Defense World
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Amicus Therapeutics (FOLD) Scheduled to Post Earnings on Wednesday - MarketBeat
Semanteon Capital Management LP Invests $1.13 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewswire
Assenagon Asset Management S.A. Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at StockNews.com - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Upgraded by StockNews.com to Buy - Defense World
Pompe Disease Market on Track for Major Expansion by 2034, - openPR
Pompe Disease Market on Track for Major Expansion by 2034, According to DelveInsight | Asklepios Biopharma, Genzyme, Sanofi, GeneCradle Inc, Astellas Gene Therapies, Amicus Therapeutics, Spark - The Globe and Mail
(FOLD) Proactive Strategies - Stock Traders Daily
Why Amicus Therapeutics (FOLD) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Given New $15.00 Price Target at Bank of America - Defense World
How Much Upside is Left in Amicus Therapeutics (FOLD)? Wall Street Analysts Think 43.44% - MSN
Creative Planning Lowers Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
What is Zacks Research’s Estimate for FOLD Q3 Earnings? - Defense World
Amicus: Teva Settlement Clears Revenue Path Forward For Galafold - Seeking Alpha
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar? - MSN
FOLD Stock Rises on Settling Galafold Patent Dispute With Teva - MSN
Can Amicus Therapeutics (FOLD) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Teva settles patent litigation with Amicus (TEVA:NYSE) - Seeking Alpha
Amicus Therapeutics (FOLD) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Zacks Research Issues Optimistic Outlook for FOLD Earnings - MarketBeat
What is Zacks Research’s Estimate for FOLD Q2 Earnings? - Defense World
Amicus Therapeutics Announces Settlement of Galafold® (migalastat) Patent Litigation with Teva - GlobeNewswire
Alnylam Stock Up on Cardiomyopathy Drug Regulatory Filing in the EU - Benzinga
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpHere's Why - MarketBeat
Amicus announces settlement of Galafold patent litigation with Teva - TipRanks
Amicus Therapeutics settles patent litigation with Teva - Investing.com
Amicus Therapeutics settles patent litigation with Teva By Investing.com - Investing.com Australia
Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug - Yahoo Finance
Amicus Therapeutics Shares Rise After Lawsuit Settlement, Deal With Teva - MarketWatch
Amicus Therapeutics, Inc. (NASDAQ:FOLD) to Post Q2 2025 Earnings of $0.01 Per Share, Zacks Research Forecasts - MarketBeat
SG Americas Securities LLC Invests $554,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Taking on analysts’ expectations and winning: Amicus Therapeutics Inc (FOLD) - SETE News
Morgan Stanley Lowers Amicus Therapeutics (NASDAQ:FOLD) Price Target to $18.00 - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Cut to Hold at StockNews.com - MarketBeat
Gaucher’s Disease Treatment Industry to Witness an Outstanding Growth by 2034 |Amicus Therapeutics, Inc., Novartis AG, S – IndiaPolitics.com - IndiaPolitics.com
Analyzing Amicus Therapeutics Inc (FOLD) After Recent Trading Activity - Knox Daily
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):